yuelan
After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest intraday gain in nearly two years and rallying its peers despite President Trump’s latest